The report forecasts the global orphan drugs market to grow at a CAGR of
10.05% over the period 2014-2019.

The report covers the current scenario and the growth prospects of the
global orphan drugs market for the period of 2015-2019. To calculate the
market size, the report considers revenue generated from the sales
orphan drugs.

According to WHO, orphan or rare diseases are the pathological
conditions that affect 0.65-1 out of 10,000 population worldwide. There
are around 6,000 orphan diseases, of which 80% are genetic. Orphan drugs
are developed by the pharmaceutical industry to serve the public health
need. These are designated as “Orphan Designations” by the regulatory
agencies to accelerate the approval process.

The report has been prepared based on an in-depth market analysis with
inputs from industry experts. The report covers the Americas, APAC, and
Europe; it also covers the landscape of the global orphan drugs market
and its growth prospects in the coming years. The report includes a
discussion of the key vendors operating in this market.